论文部分内容阅读
1970年在瑞士召开的欧洲呼吸生理及临床协会第六届会议和1981年11月在香港举行的第七届亚洲-太平洋地区胸科疾病会议上,都对治疗哮喘新药酮替芬(Ketotifen亦称噻哌酮)的作用机理和临床效果进行了讨论。根据动物实验和人白细胞体外组胺释放系统的研究结果,酮替芬对IgE介导的特应性哮喘和非IgE介导的非特应性哮喘均有作用,也即对内源性及外源性哮喘均有一定疗效,故该药为一广谱抗哮喘药。酮替芬的药理作用动物实验证明该药能抑制被动性皮肤过敏反应,这种作用与抗
The sixth meeting of the European Respiratory Physiological and Clinical Society in Switzerland in 1970 and the Seventh Asian Pacific Thoracic Disease Conference in November 1981 all had therapeutic benefits for the treatment of the new drug ketotifen (also known as Ketotifen Thiophene ketone) mechanism of action and clinical effects were discussed. Based on animal experiments and studies of human leukocyte histamine release system in vitro, ketotifen has an effect on both IgE-mediated atopic asthma and non-IgE-mediated non-atopic asthma, ie, both endogenous and exogenous Sexual asthma have a certain effect, so the drug is a broad-spectrum anti-asthma drugs. Pharmacological effects of ketotifen Animal experiments show that the drug can inhibit passive skin allergic reactions, this effect with anti